O.A. Rubanenko, I.A. Zolotovskaya., P.R. Shatskaya
Modern methods of thrombosis prevention and treatment in cancer patients with atrial fibrillation: focus on apixaban
|
№7 / 2024
|
Shatalova N.A., Mirzaev K.B., Abdullaev Sh.P., Sozaeva Zh.A., Bochkov P.O., Asoskova A.V., Denisenko N.P., Kochetkov A.I., Ebzeeva E.Yu., Chernyaeva M.S., Shastina V.R., Ostroumova O.D., Sychev D.A.
On the possible relationship between the presence of polymorphic variants of CYP3A4/5 cytochrome genes, their metabolic activity with rivaroxaban pharmacokinetics and the development of bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease
|
№1 / 2024
|
E.A. Ulrikh
Venous thrombosis and malignant gynecological diseases: the place of direct oral anticoagulants in prevention
|
№11 / 2023
|
A.I. Tarzimanova
Modern principles of antiarrhythmic therapy of atrial fibrillation
|
№1-2 / 2023
|
O.A. Mubarakshina, M.N. Somova, G.A. Batishcheva
Nadroparin in the treatment of unstable angina and myocardial infarction: a point of view of a clinical pharmacologist
|
№13 / 2022
|
L.B. Novikova, A.P. Akopyan, Kh.M. Mustafin, N.S. Khabibrakhmanova, I.I. Kayumova
RISK FACTORS FOR CEREBROVASCULAR DISEASES IN NEUROGERIATRY
|
№9 / 2017
|
P.R. Kamchatnov (1), M.A. Evzelman (2), I.V. Evgrafov (3)
EFFICACY AND SAFETY OF SECONDARY PREVENTION OF ISCHEMIC STROKE USING ANTIPLATELET AGENTS AND ORAL ANTICOAGULANTS
|
№13 / 2015
|
M.G. Glezer
NEW ORAL ANTICOAGULANTS IN THE PREVENTION OF VENOUS THROMBOSIS AND THROMBOEMBOLISM: FOCUS ON RIVAROXABAN
|
№13 / 2014
|
G.A.Baryshnikova
MODERN POSSIBILITIES OF STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION
|
№6 / 2014
|
M.A. Domashenko, M.Yu. Maximova, M.M. Tanashyan
Secondary Drug Prevention Of Ischemic Stroke
|
№14 / 2012
|
D.A. Zateyshcikov, I.V. Zotova
Dabigatran: Prospects For Clinical Application
|
№15 / 2011
|
MM. Tanasjn, M.A. Domashenko С. 2027
Current Principles Of Management Of Patients Experienced Acute Cerebral Circulation Disorder At Out-patient Stage
|
№10 / 2009
|